Clinical trial · Interventional
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
NCT00165048CI-TRIAL-00000234unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the effect of selective COX-II inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection (so called R1 or R2 gastrectomy).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Stomach | Malignant Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Vioxx (Rofecoxib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Symptom-free susrvival and the quality of life score within the two years of study period.
Secondary outcomes (1)
- measure
- Overall survival in long-term.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Stomach cancer with peritoneal or lymphatic spread beyond the scope of curative resection * Palliative resection can be performed * Normal RFT Exclusion Criteria: * Solid organ metastases * Poor performance status * On long-term aspirin or NSAID * Renal or hepatic dysfunction * Bleeding disorder * Hypersensitive to COX-II inhibitors/aspirin/NSAID * No history of myocardial infarct or stroke
References
Publications (0)
Data not yet available
No reference posted for this study.